A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
=== Role as chaperone === Several heat shock proteins function as intra-cellular chaperones for other proteins. They play an important role in protein–protein interactions such as folding and assisting in the establishment of proper protein conformation (shape) and prevention of unwanted protein aggregation. By helping to stabilize partially unfolded proteins, HSPs aid in transporting proteins across membranes within the cell. Some members of the HSP family are expressed at low to moderate levels in all organisms because of their essential role in protein maintenance.
=== Persons with disabilities === During 2025, the Karnataka Labour Department worked on a proposed legislative framework for reservations for persons with disabilities in education and private-sector employment. The draft framework proposed up to 10 percent reservation in educational institutions and 5 percent in private-sector employment, subject to legislative and policy processes.
=== Film and television productions === Several films and television series have been filmed in West Yorkshire's historic areas, particularly around the town of Halifax. For example, portions of the BBC television series Happy Valley were filmed in Huddersfield; in addition to exteriors, some of the studio filming was done at North Light Film Studios at Brookes Mill, Huddersfield. As well, interiors for the BBC's Jamaica Inn, for the BBC's Remember Me and for ITV series Black Work, were also filmed at the studios. More recently, many of the exteriors of the BBC series Jericho were filmed at the nearby Rockingstone Quarry and some interior work was done at North Light Film Studios.
Sources: en.wikipedia.org
=== Cancer === The role of iron in cancer defense can be described as a "double-edged sword" because of its pervasive presence in non-pathological processes. People having chemotherapy may develop iron deficiency and anemia, for which intravenous iron therapy is used to restore iron levels. Iron overload, which may occur from high consumption of red meat, may initiate tumor growth and increase susceptibility to cancer onset, particularly for colorectal cancer.
Muscle fatigue may be due to problems with the nerve supply, neuromuscular disease (such as myasthenia gravis), inborn errors of metabolism (such as metabolic myopathies), or problems with muscle itself. The latter category includes polymyositis and other muscle disorders.
=== Government === Government – Official website of Government of Malaysia National Palace – official website of the king of Malaysia Prime Minister – official website of the prime minister of Malaysia Parliament – official website of Parliament of Malaysia Federal Court Archived 18 July 2025 at the Wayback Machine – official website of the Chief Registrar of the Federal Court of Malaysia Statistics – official website of the Department of Statistics Malaysia
Sources: en.wikipedia.org
This can be due to any number of factors, including improved nutrition resulting in rapid body growth, increased weight and fat deposition, or exposure to endocrine disruptors such as xenoestrogens, which can at times be due to food consumption or other environmental factors. However, more modern archeological research suggests that the rate of puberty as it occurs now is comparable to other time periods. Growth spurts began at around 10–12, but markers of later stages of puberty such as menarche had delays that correlated with severe environmental conditions such as poverty, poor nutrition, and air pollution. Puberty that starts earlier than usual is known as precocious puberty, and puberty which starts later than usual is known as delayed puberty. Notable among the morphologic changes in size, shape, composition, and functioning of the pubertal body, is the development of secondary sex characteristics, the "filling in" of the child's body; from girl to woman, from boy to man. Derived from the Latin puberatum (age of maturity), the word puberty describes the physical changes to sexual maturation, not the psychosocial and cultural maturation denoted by the term adolescent development in Western culture, wherein adolescence is the period of mental transition from childhood to adulthood, which overlaps much of the body's period of puberty.
=== Judiciary === The judicial system was a typical hierarchical structure consisting of lower courts, a High Court and a Court of Appeal. Successive chief justices were Sir Stafford Foster-Sutton (1950–1951) (afterwards Chief Justice of Nigeria, 1955), Sir Charles Mathew (1951–1956) and Sir James Beveridge Thomson (1957–1963).
==== Needs of the aquaculture sector in vaccines ==== Aquaculture has an average annual growth rate of 9.2%, however, the success and continued expansion of the fish farming sector is highly dependent on the control of fish pathogens including a wide range of viruses, bacteria, fungi, and parasites. In 2014, it was estimated that these parasites cost the global salmon farming industry up to 400 million Euros. This represents 6–10% of the production value of the affected countries, but it can go up to 20% (Fisheries and Oceans Canada, 2014). Since pathogens quickly spread within a population of cultured fish, their control is vital for the sector. Historically, the use of antibiotics was against bacterial epizootics but the production of animal proteins has to be sustainable, which means that preventive measures that are acceptable from a biological and environmental point of view should be used to keep disease problems in aquaculture at an acceptable level. So, this added to the efficiency of vaccines resulted in an immediate and permanent reduction in the use of antibiotics in the 90s. In the beginning, there were fish immersion vaccines efficient against the vibriosis but proved ineffective against the furunculosis, hence the arrival of injectable vaccines: first water-based and after oil-based, much more efficient (Sommerset, 2005).
The Lord Ramage series by Dudley Pope takes place during the Napoleonic Wars. Jeanette Winterson's 1987 novel The Passion. Georgette Heyer's 1937 novel An Infamous Army recounts the fortunes of a family in the run-up to and during the course of, the Battle of Waterloo. Heyer's novel is noted for its meticulous research on the progress of the battle, combining her noted period romance writing with her detailed research into regency history. The Battle (French: La Bataille) is a historical novel by the French author Patrick Rambaud that was first published in 1997 and again in English in 2000. The book describes the 1809 Battle of Aspern-Essling between the French Empire under Napoleon and the Austrian Empire. The novel was awarded the Prix Goncourt and the Grand Prix du roman de l'Académie française for 1997. In Jasper Kent's novel Twelve, 1812 Russian Invasion serves as a base story for the book. In later books from The Danilov Quintet, this war is constantly mentioned. The Fighting Sail series by Alaric Bond portrays life and action aboard Royal Naval vessels during the Revolutionary and Napoleonic Wars. From the lower decks to the quarterdeck Bond's detailed settings are realistic. Narratives are told not just from a commissioned officer's point of view but include varied perspectives, including warranted officers, ordinary and able seamen, marines, supernumeraries, and women aboard presenting a broader, more complete picture of the Georgian Navy.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.